UDP-glucuronosyltransferase 1A6 is the major isozyme responsible for protocatechuic aldehyde glucuronidation in human liver microsomes

Drug Metabolism and Disposition

Volumn 36, Issue 8, 2008, Pages 1562-1569

  Liu, Hui Xin ^a,b   Liu, Yong ^a   Zhang, Jiang Wei ^a,b   Li, Wei ^b   Liu, Hong Tao ^a,b   Yang, Ling ^a  

^a DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTERONE; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A9; PHENYLBUTAZONE; PROTOCATECHUALDEHYDE; SALVIA MILTIORRHIZA EXTRACT;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG GLUCURONIDATION; ENZYME METABOLISM; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; INHIBITION KINETICS; INTESTINE MICROSOME; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; LIVER MICROSOME METABOLISM; MASS SPECTROMETRY; METABOLITE; MICHAELIS MENTEN KINETICS; MICROSOME; PRIORITY JOURNAL; SALVIA MILTIORRHIZA;

BENZALDEHYDES; BIOTRANSFORMATION; CATECHOLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; ISOENZYMES; MICROSOMES, LIVER; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 47949090607     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.020560     Document Type: Article

References (39)

1. Antonio L, Grillasca JP, Taskinen J, Elovaara E, Burchell B, Piet MH, Ethell B, Ouzzine M, Fournel-Gigleux S, and Magdalou J (2002) Characterization of catechol glucuronidation in rat liver. Drug Metab Dispos 30:199-207.
2. Baba S, Osakabe N, Natsume M, and Terao J (2004) Orally administered rosmarinic acid is present as the conjugated and/or methylated forms in plasma, and is degraded and metabolized to conjugated forms of caffeic acid, ferulic acid and m-coumaric acid. Life Sci 75:175-178.
3. Bauman JN, Goosen TC, Tugnait M, Peterkin V, Hurst SI, Menning LC, Milad M, Court MH, and Williams JA (2005) UDP-glucuronosyltransferase 2b7 is the major enzyme responsible for gemcabene glucuronidation in human liver microsomes. Drug Metab Dispos 33:1349-1354.
4. Bosma PJ, Seppen J, Goldhoorn B, Bakker C, Oude Elferink RP, Chowdhury JR, Chowdhury NR, and Jansen PL (1994) Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J Biol Chem 269:17960-17964.
5. Chang PN, Mao JC, Huang SH, Ning L, Wang ZJ, On T, Duan W, and Zhu YZ (2006) Analysis of cardioprotective effects using purified Salvia miltiorrhiza extract on isolated rat hearts. J Pharmacol Sci 101:245-249.
6. Ciotti M, Marrone A, Potter C, and Owens IS (1997) Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implications. Pharmacogenetics 7:485-495.
7. Court MH, Duan SX, von Moltke LL, Greenblatt DJ, Patten CJ, Miners JO, and Mackenzie PI (2001) Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ther 299:998-1006.
8. Court MH, Krishnaswamy S, Hao Q, Duan SX, Patten CJ, Von Moltke LL, and Greenblatt DJ (2003) Evaluation of 3′-azido-3′-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos 31:1125-1133.
9. De Buck SS and Mackie CE (2007) Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation. Expert Opin Drug Metab Toxicol 3:865-878.
10. Di Marco A, D'Antoni M, Attaccalite S, Carotenuto P, and Laufer R (2005) Determination of drug glucuronidation and UDP-glucuronosyltransferase selectivity using a 96-well radiometric assay. Drug Metab Dispos 33:812-819.
11. Ding M, Ye TX, Zhao GR, Yuan YJ, and Guo ZX (2005) Aqueous extract of Salvia miltiorrhiza attenuates increased endothelial permeability induced by tumor necrosis factor-α. Int Immunopharmacol 5:1641-1651.
12. Ebner T, Remmel RP, and Burchell B (1993) Human bilirubin UDP-glucuronosyltransferase catalyzes the glucuronidation of ethinylestradiol. Mol Pharmacol 43:649-654.
13. Ethell BT, Anderson GD and Burchell B (2003) The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP- glucuronosyltransferases. Biochem Pharmacol 65:1441-1449.
14. Gradinaru D, Suleman FG, Leclerc S, Heydel JM, Grillasca JP, Magdalou J, and Minn A (1999) UDP-glucuronosyltransferase in the rat olfactory bulb: identification of the UGT1A6 isoform and age-related changes in 1-naphthol glucuronidation. Neurochem Res 24:995-1000.
15. Guengerich PF (1989) Analysis and characterization of enzymes, in Principles and Methods of Toxicology (Hayes AW ed) pp 777-813, Raven Press, New York.
16. Han S, Liu E, and Li H (2005) On-line chemiluminescence determination protocatechuic aldehyde and protocatechuic acid in pharmaceutical preparations by capillary electrophoresis. J Pharm Biomed Anal 37:733-738.
17. Iyanagi T (2007) Molecular mechanism of phase I and phase II drug-metabolizing enzymes: implications for detoxification. Int Rev Cytol 260:35-112.
18. Kessler FK, Kessler MR, Auyeung DJ, and Ritter JK (2002) Glucuronidation of acetaminophen catalyzed by multiple rat phenol UDP-glucuronosyltransferases. Drug Metab Dispos 30:324-330.
19. King CD, Rios GR, Green MD, and Tephly TR (2000) UDP- glucuronosyltransferases. Curr Drug Metab 1:143-161.
20. Konishi Y, Hitomi Y, Yoshida M, and Yoshioka E (2005) Pharmacokinetic study of caffeic and rosmarinic acids in rats after oral administration. J Agric Food Chem 53:4740-4746.
21. Krishnaswamy S, Duan SX, von Moltke LL, Greenblatt DJ, and Court MH (2003) Validation of serotonin (5-hydroxtryptamine) as an in vitro substrate probe for human UDPglucuronosyltransferase (UGT) 1A6. Drug Metab Dispos 31:133-139.
22. Krishnaswamy S, Hao Q, von Moltke LL, Greenblatt DJ, and Court MH (2004) Evaluation of 5-hydroxytryptophol and other endogenous serotonin (5-hydroxytryptamine) analogs as substrates for UDP-glucuronosyltransferase 1A6. Drug Metab Dispos 32:862-869.
23. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
24. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS, and Nebert DW (2005) Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15:677-685.
25. Mano Y, Usui T, and Kamimura H (2007) The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver. Drug Metab Dispos 35:2040-2044.
26. Martinasevic MK, King CD, Rios GR, and Tephly TR (1998) Immunohistochemical localization of UDP-glucuronosyltransferases in rat brain during early development. Drug Metab Dispos 26:1039-1041.
27. Münzel PA, Bookjans G, Mehner G, Lehmköster T, and Bock KW (1996) Tissue-specific 2,3,7,8-tetrachlorodibenzo-p-dioxin-inducible expression of human UDP-glucuronosyltransferase UGT1A6. Arch Biochem Biophys 335:205-210.
28. Nagar S, Zalatoris JJ, and Blanchard RL (2004) Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells. Pharmacogenetics 14:487-499.
29. Ouzzine M, Pillot T, Fournel-Gigleux S, Magdalou J, Burchell B, and Siest G (1994) Expression and role of the human liver UDP-glucuronosyltransferase UGT1*6 analyzed by specific antibodies raised against a hybrid protein produced in Escherichia coli. Arch Biochem Biophys 310:196-204.
30. Radominska-Pandya A, Czernik PJ, Little JM, Battaglia E, and Mackenzie PI (1999) Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev 31:817-899.
31. Strassburg CP, Kneip S, Topp J, Obermayer-Straub P, Barut A, Tukey RH, and Manns MP (2000) Polymorphic gene regulatin and interindividual variatin of UDP-glucuronosyltransferase activity in human small intestine. J Biol Chem 275:36164-36171.
32. Strassburg CP, Nguyen N, Manns MP, and Tukey RH (1999) UDP-glucuronosyltransferase activity in human liver and colon. Gastroenterology 116:149-160.
33. Strassburg CP, Oldhafer K, Manns MP, and Tukey RH (1997) Differential expression of the UGT1A locus in human liver, biliary and gastric tissue: identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue. Mol Pharmacol 52:212-220.
34. Sugiyama A, Zhu BM, Takahara A, Satoh Y, and Hashimoto K (2002) Cardiac effects of Salvia miltiorrhiza/Dalbergia odorifera mixture, an intravenously applicable Chinese medicine widely used for patients with ischemic heart disease in China. Circ J 66:182-184.
35. Uchaipichat V, Mackenzie PI, Elliot DJ, and Miners JO (2006) Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human UDP-glucuronosyltransferases. Drug Metab Dispos 34:449-456.
36. Xu M, Fu G, Qiao X, Wu WY, Guo H, Liu AH, Sun JH, and Guo DA (2007a) HPLC method for comparative study on tissue distribution in rat after oral administration of salvianolic acid B and phenolic acids from Salvia miltiorrhiza. Biomed Chromatogr 21:1052-1063.
37. Xu M, Zhang Z, Fu G, Sun S, Sun J, Yang M, Liu A, Han J, and Guo DA (2007b) Liquid chromatography-tandem mass spectrometry analysis of protocatechuic aldehyde and its phase I and II metabolites in rat. J Chromatogr B Analyt Technol Biomed Life Sci 856:100-107.
38. Ye G, Wang CS, Li YY, Ren H, and Guo DA (2003) Simultaneous determination and pharmacokinetic studies on (3,4-dihydroxyphenyl)-lactic acid and protocatechuic aldehyde in rat serum after oral administration of Radix Salviae miltiorrhizae extract. J Chromatogr Sci 41:327-330.
39. Zhou Z, Liu Y, Miao AD, and Wang SQ (2005) Protocatechuic aldehyde suppresses TNF-α-induced ICAM-1 and VCAM-1 expression in human umbilical vein endothelial cells. Eur J Pharmacol 513:1-8.